Prevalence of Human Papillomavirus infection among Chilean women from 2012 to 2016
Author
dc.contributor.author
Vergara, Nicolás
Author
dc.contributor.author
Espinoza, Gloria
Author
dc.contributor.author
Balanda, Monserrat
Author
dc.contributor.author
Quiero, Andrea
Author
dc.contributor.author
Hidalgo, Wilma
Author
dc.contributor.author
San Martín, Héctor
Author
dc.contributor.author
Ramírez, Alejandro
Author
dc.contributor.author
Ramírez, Eugenio
Admission date
dc.date.accessioned
2019-03-18T11:56:24Z
Available date
dc.date.available
2019-03-18T11:56:24Z
Publication date
dc.date.issued
2017
Cita de ítem
dc.identifier.citation
Journal of Medical Virology, 2017 ; 89 : 1646–1653
Identifier
dc.identifier.issn
10969071
Identifier
dc.identifier.issn
01466615
Identifier
dc.identifier.other
10.1002/jmv.24805
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/167106
Abstract
dc.description.abstract
Here, we evaluated the prevalence of Human Papillomavirus (HPV) in two groups of Chilean
women. The first group consisted of 3235 womenaged 18-64 years attended in six primary care
centers of Santiago. The second group consisted of 456 women 18-85 aged who consulted the
Gynaecology Department of the Reference Hospital of Santiago. Samples were collected from
October 2012 to February 2016. Cervical swabs were analyzed both HPV genotyping by PCR
and Reverse Line Blot, and cervical cytology by Pap testing. Results showed a prevalence of
12.0% HPV positive, 10.3% high-risk (HR) HPV types positive, 3.9% low-risk (LR) HPV types
positive, and 1.0% Pap positive in group 1. The most frequent types were 16, 66, and 59, with a
prevalence of 3.0%, 1.6%, and 1.5%, respectively. The prevalence were 71.9% HPV positive,
67.3%HR-HPVtypes positive, 13.6% LR-HPV types positive, and 62.5% Pap positive in group 2.
The most frequent types were 16, 31, and 58, with prevalence of 33.6%, 10.5%, and 7.0%,
respectively. Among infected women with HPV: 7.6% were infected with HPV16 or HPV18,
3.0% with HPV31, HPV33 or HPV45, and 6.7% with any other HR-HPV. These findings show
great difference in HPV prevalence and types between primary care and reference center, and
provide useful epidemiological information to assess the impact of HPV vaccination in the
future.